All Projects (115)

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Nikitenko Jan 1, 2023 - Dec 31, 2025

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Ettelaie Jan 1, 2024 - Dec 31, 2025

TEM-PAC 2: Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions - Maraveyas Sep 1, 2024 - Aug 31, 2025

BREEZE 2: A randomised controlled trial of a complex intervention to manage breathlessness in pulmonary fibrosis Apr 1, 2024 - Mar 31, 2026
Full trial based on BREEZE feasibility trial

ACF 2023-2026 Sep 1, 2023 - Aug 31, 2026

LCD SAFE Nov 1, 2022 - Apr 30, 2024
SAFE-LCD: Can the combination of continuous glucose monitoring and a digital low calorie diet programme make Type 2 diabetes remission achievable and safe in people on insulin therapy?

A multi-centre, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease. Dec 1, 2022 - Nov 30, 2023
ILD

Freeman Fellowship in Diabetes and Endocrinology Apr 1, 2023 - Mar 31, 2030
This is for five PhD studentships to run consecutively over five years in the first instance.

A Randomised, Double-blind, Placebo-controlled Phase 2 Study with Open-label Extension to Assess the Efficacy and Safety of Namilumab in Subjects with Chronic Pulmonary Sarcoidosis Jan 1, 2023 - Aug 31, 2025

Wolfson Equipment bid 2023 - Confocal Imaging ZEISS Elyra 7 with Lattice SIM² Oct 1, 2024 - Sep 30, 2029

THrough knee AMputation impact on Quality of Life compared to abovE knee amputaTion (HAMLET) Jun 1, 2024 - Aug 31, 2030
HAMLET Trial – Through knee or not through knee

Phase 2 Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients with IPF May 1, 2022 - Jun 30, 2024

PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS EFZOFITIMOD IN PATIENTS WITH PULMONARY SARCOIDOSIS Jan 1, 2023 - Jun 30, 2025

RDS Amputation PPI Apr 1, 2023 - Mar 31, 2024

The DRESSINg trial: A multicentre randomised controlled trial to assess the effectiveness of Dialkylcarbamoylchloride (DACC) coated post-operative dressings versus standard care in the prevention of Surgical Site Infection in clean or clean contaminated vascular surgery Oct 1, 2023 - Sep 30, 2026
Aims
This study aims to investigate the role of a new dressing (DACC) in preventing wound infection follow vascular surgery. This dressing has a special coating that binds to bacteria irreversibly, allowing them to be removed. The DACC dressings wil... Read More about The DRESSINg trial: A multicentre randomised controlled trial to assess the effectiveness of Dialkylcarbamoylchloride (DACC) coated post-operative dressings versus standard care in the prevention of Surgical Site Infection in clean or clean contaminated vascular surgery.

HIKE: A Data Package to Support Clinical Translation of Novel Microwave Probes for Peripheral Arterial Disease (MICRO-PAD) Nov 1, 2023 - Mar 3, 2025
This project will combine HYMS/Hull’s biomedical and clinical expertise in vascular biology with Emblation’s track record in bringing medical devices to market to validate and commercialise novel patented microwave probes for treatment of peripheral... Read More about HIKE: A Data Package to Support Clinical Translation of Novel Microwave Probes for Peripheral Arterial Disease (MICRO-PAD).

HEIF: Simplifying patient information for clinical trials Aug 1, 2023 - Jul 31, 2024
Clinical trials are the main mechanism for improving patient care. They are an important source of income for the University and HUTH. The output in terms of publications and impact generated contributes greatly to the REF submission.

In order to... Read More about HEIF: Simplifying patient information for clinical trials.

Understanding barriers and facilitators to implementing physical activity interventions for patients receiving immune checkpoint inhibitor therapy: A qualitative study Nov 1, 2023 - Jul 31, 2026
Immune checkpoint inhibitors (ICIs) have huge potential for the treatment of metastatic melanoma, renal, head and neck, and lung cancers. While recent research shows that exercise improves chemoradiotherapy outcomes, its role as an adjunctive treatme... Read More about Understanding barriers and facilitators to implementing physical activity interventions for patients receiving immune checkpoint inhibitor therapy: A qualitative study.

A Phase 3, 24 week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937 in Adult Participants with Refractory Chronic COugh Including Unexplained Chronic COugh (CALM-2) Jul 1, 2023 - Apr 30, 2026

Phase 3 Study to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED): IMVT-1401-3201 TED GO-1 Nov 1, 2023 - Apr 30, 2027
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab for the Treatment of Thyroid Eye Disease (TED)